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Abstract
Background: Angiosarcoma of the breast is very rare and can be divided into primary and secondary
angiosarcoma. Radiation-induced angiosarcoma (RIAS) is classified as secondary angiosarcoma. Diagnosis of RIAS is
difficult due to its rarity, and the interpretation of pathological imaging is complicated. In the National
Comprehensive Care Network (NCCN) guidelines, the first choice of treatment is surgery with negative margins.
Adjuvant radiotherapy (RT) for close soft tissue margins should be considered. Preoperative or adjuvant
chemotherapy of nonmetastatic disease is not recommended for angiosarcoma. We report a case of RIAS, which
was impossible to diagnose with core needle biopsy (CNB) but was diagnosed by excisional biopsy. The patient
was then administered adjuvant chemotherapy using conjugated paclitaxel (PTX).
Case presentation: A 62-year-old woman noticed a tumor in her right breast. She had a history of right breast
cancer and had undergone breast-conserving surgery, RT, and tamoxifen therapy 8 years previously. CNB, which
was performed twice, was inconclusive. The tumor was surgically excised and pathological analysis yielded a
diagnosis of angiosarcoma. She then underwent a right mastectomy. One month after she underwent right
mastectomy, a nodule reappeared on the skin of her right breast, and excisional biopsy revealed recurrence of
angiosarcoma. A few weeks later another nodule reappeared near the post-operative scar and excisional biopsy
revealed recurrence of angiosarcoma. We assumed that surgical therapy was insufficient because the patient
experienced relapse of angiosarcoma after complete mastectomy. After the second recurrence, we treated her with
systemic chemotherapy using PTX. There was no evidence of recurrence 8 months after chemotherapy.
Conclusion: Although angiosarcoma is difficult to diagnose, many patients have a poor prognosis. Therefore,
prompt treatment intervention is desired. Moreover, there is little evidence regarding adjuvant therapy of
angiosarcoma since it is a rare disease. We consider that adjuvant therapy helped to effectively prevent recurrence
in the patient after complete excision.
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Background
Angiosarcoma is an extremely rare, malignant, blood vessel
tumor. Angiosarcoma of the breast can be divided into pri-
mary angiosarcoma and secondary angiosarcoma.
Radiation-induced angiosarcoma (RIAS) is classified as sec-
ondary angiosarcoma. In patients undergoing breast-
conserving surgery (BCS) with adjuvant radiotherapy, the
estimated incidence of RIAS is 0.05–0.3% [1]. In the last
few decades, BCS followed by radiotherapy (RT) has be-
come one of the standard treatments. In addition, postoper-
ative radiotherapy has been performed in many cases with
positive axillary node metastasis. Moreover, the number of
patients who receive RT is estimated to increase in the fu-
ture [2]. However, due to difficulties in the diagnosis of
angiosarcoma with fine needle aspiration (FNA) or core
needle biopsy (CNB), misdiagnosis is frequently reported,
delaying the radical surgery [3, 4]. Nonmetastatic angiosar-
coma is treated with surgical resection [5]. However, evi-
dence regarding the use of adjuvant therapy for the
treatment of breast angiosarcoma is limited and needs care-
ful consideration. Here, we describe a case of angiosarcoma
in a patient, who underwent a mastectomy for primary
breast cancer 8 years prior and was treated for recurring
angiosarcoma with chemotherapy using paclitaxel (PTX).
Case presentation
A 62-year-old woman had a history of right breast cancer
and had undergone BCS. Pathologically, the tumor was clas-
sified as pT1cN0M0 pStageIA. Adjuvant RT (50Gy) was ad-
ministered to the residual breast tissue followed by
hormone therapy (tamoxifen 20mg daily for 5 years). There
was no evidence of recurrence. However, 8 years after the
first surgery, a tumor measuring 3 cm in size, appeared cuta-
neously in her right breast. The inside of the tumor had a
low echoic area and the tumor borders were unclear on
ultrasonography (Fig. 1a). CNB was performed twice and
the bloody tissue was collected; however, it did not reveal a
definitive diagnosis (Fig. 2a, b). Two months later, the tumor
had grown bigger (Fig. 1b). CNB was performed again, but
it did not reveal a definitive diagnosis. PET/CT showed ac-
cumulation in the tumor and no metastatic disease (Fig. 3a,
b). We suspected that the tumor was angiosarcoma because
of her medical history as well as the examination results.
Fig. 1 a Ultrasonographic images of the patient with the tumor. The inside of the tumor had a low echoic area, and the tumor borders were
unclear. b The tumor grew larger 2 months later
Fig. 2 Pathological analyses of core-needle-biopsy. The endothelial
cells were swollen; however, atypical epithelial cells were absent. a
× 40; b × 200
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Fig. 3 a PET/CT before the surgery showed no metastatic disease. b PET/CT showed accumulation in the tumor
Suzuki et al. Surgical Case Reports            (2020) 6:25 Page 3 of 7
Fig. 5 The patient underwent a right mastectomy. There was residual disease (red dotted area). The resection margin was negative. a The whole
sample. b, c The cross-section of the sample
Fig. 4 The excisional biopsy yielded the diagnosis of angiosarcoma. The resection margin was positive. a The whole sample. b The cross-section
of the sample
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First, she had received RT after BCS. Second, the tumor had
grown rapidly. Third, PET/CT had suggested the presence
of malignant disease. She received an excisional biopsy and
the pathological analysis yielded a diagnosis of angiosarcoma
(Fig. 4). Subsequently, mastectomy was performed (Fig. 5)
and the pathological analysis yielded a diagnosis of residual
angiosarcoma (Fig. 6a, b) because of strong positive staining
with antibodies against CD31 and EGFR (Fig. 6c, d). The
tumor differentiation status was Federation Nationale des
Centres de Lutte Contre le Cancer (FNCLCC) Grade 3
(tumor differentiation: score 3, mitotic count: score 3, tumor
necrosis: score 0). The surgical margin was negative. We
discussed the need for adjuvant chemotherapy using PTX.
One month after the surgery, a nodule appeared on the skin
around the surgical scar, which was confirmed as a recur-
rence of angiosarcoma by excisional biopsy. A few weeks
later, a nodule reappeared on the skin around the surgical
scar and was identified as a second recurrence of angiosar-
coma by excisional biopsy. Subsequently, she underwent
chemotherapy with PTX. There was no recurrence for 8
months following the second recurrence.
Discussion
Angiosarcoma is an uncommon, malignant, blood vessel
tumor. Angiosarcoma of the breast comprises 0.05% of all
malignant tumors of the breast [2]. Cohen-Hallaleh et al.
reported that the median age of diagnosis of the RIAS was
72 years (range 51–92 years) and the median time from
completion of RT to the diagnosis of RIAS was 7.5 years
(range 1–26 years) [1]. In our case, the age at diagnosis was
lower than the median age, the duration from completion of
radiation to the diagnosis of RIAS was similar to the median
time. Patients with RIAS have a wide variety of cutaneous
symptoms, for example, they experience purpura, erythema,
ulcers, and edema. Because of the rarity of RIAS and the
variety of symptoms, it is frequently misdiagnosed as a
hematoma from injury, X-ray dermatitis [3], or contact
dermatitis [4]. Cahan et al. established the criteria to diag-
nose RIAS which include the following: (1) history of RT,
(2) asymptomatic latency period of several years (5 or more),
(3) occurrence of sarcoma within a previously irradiated
field, and (4) histologic confirmation of the sarcomatous na-
ture [6]. The diagnosis from fine needle aspiration cytology
(FNAC) or the CNB before radical surgery is very difficult.
Strobbe et al. reported that the diagnosis rate of angiosar-
coma by FNAC is 22% [7]. The reasons for this are as fol-
lows. First, angiosarcoma has a variety of morphological
cellular features and in some cases, and it is misdiagnosed
as a benign hemangioma [4]. Second, in contrast to primary
angiosarcoma of the breast, malignant cells of recurring
post-RT angiosarcoma typically have poorly differentiated
nuclei with vesicular chromatin, prominent nucleoli, and
Fig. 6 a Pathological analysis of the mastectomy revealed atypical cells that formed vascular spaces. (H-E) b Atypical cells proliferated. The
cellularity of the block was very high. (H-E) c The endothelial cells showed strong positive staining with antibodies against CD31. d The nucleus
showed strong positive staining with antibodies against EGFR
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mitotic activity [8]. Third, angiosarcoma of the breast is very
rare. Therefore, if the definitive diagnosis could not be made
from FNAC or CNB, excisional biopsy should be considered
if criteria (1)–(3) are fulfilled. Our patient met the criteria
(1)–(3) but did not fulfill criterion (4) before the excisional
biopsy. However, we suspected angiosarcoma because the
tumor had grown larger and PET/CT showed accumulation
in the tumor. Regarding treatment as per the National Com-
prehensive Care Network (NCCN) guidelines, angiosarcoma
is listed under soft tissue sarcoma [5]. The description of
angiosarcoma itself is limited. The first choice of therapy is
complete excision of the tumor with an adequate margin.
Adjuvant RT should be considered for close soft tissue mar-
gins but it should not be routinely administered due to ad-
verse events. In the NCCN guidelines for soft tissue
sarcoma, adjuvant chemotherapy is not recommended for
angiosarcoma. However, in patients with RIAS, some case
reports have suggested that only surgical therapy is insuffi-
cient. There has been no study to investigate the effect of
adjuvant chemotherapy on nonmetastatic, resectable angio-
sarcoma. There were a few case reports that discussed the
effect of adjuvant chemotherapy on angiosarcoma. Naka-
mura et al. reported a case in which a woman, who was di-
agnosed with breast RIAS without metastasis, had
undergone mastectomy and adjuvant chemotherapy of
weekly PTX and the patient experienced no recurrence for
15months [4]. On the contrary, Michigami et al. reported a
case of a woman, who was diagnosed with primary angiosar-
coma with no metastasis and had undergone conserving
surgery, received IL-2 therapy, and experienced recurrence
of angiosarcoma [9]. There is no prospective trial study to
evaluate whether adjuvant chemotherapy should be recom-
mended for resectable angiosarcoma. There is one prospect-
ive report about hyper-fractionated and accelerated RT.
Tamara L. Smith et al. reported that hyper-fractionated and
accelerated RT, with or without subsequent surgery,
achieved higher rates of local control, disease-free survival,
and overall survival of RIAS than the control [10]. Nicolas
Panel et al. suggested that weekly PTX administration was
well-tolerated and demonstrated clinical benefits in an
ANGIOTAX study [11]. For metastatic soft tissue sarcoma,
Winette T A van der Graaf et al. reported that Pazopanib
prolonged progression-free survival as compared to the con-
trol [12]. In the NCCN guidelines, regimens such as doce-
taxel, PTX, and vinorelbine are recommended as systematic
therapy for angiosarcoma [5]. In the NCCN guidelines for
soft tissue sarcoma, resectable local recurrence should be
excised and a decision regarding the use of radiation should
be made case-by-case.
Conclusion
Since it is difficult to diagnose angiosarcoma based on
CNB or ABC, an excisional biopsy should be taken into
consideration. In the case of angiosarcoma with no
metastasis, adjuvant chemotherapy is not the usual mode
of treatment unless there is a risk of recurrence. How-
ever, in patients who experience recurrence several times
adjuvant chemotherapy may be considered to prevent
distant metastasis.
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